The DOI matches its Crossref record.
Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.
Abstract
PURPOSE: This phase II trial was designed to evaluate the feasibility, toxicity, response rates, and survival for neoadjuvant chemotherapy and radiotherapy (RT) followed by surgical resection in newly diagnosed patients with surgically staged IIIA non-small-cell lung carcinoma (NSCLC). PATIENTS AND METHODS: Previously untreated patients with NSCLC underwent bronchoscopy, chest and abdominal computed tomography (CT), bone scan, and surgical staging of the mediastinum. Neoadjuvant treatment consisted of concurrent chemotherapy and RT. Patients then underwent surgical resection, which was followed in turn by additional chemotherapy and RT. Chemotherapy included cisplatin 100 mg/m2 on days 1 and 29, vinblastine 3 mg/m2 on days 1 and 3 and 29 and 31, and fluorouracil (5-FU) 30 mg/kg/d by infusion on days 1 to 3 and 29 to 31 (FVP). RT began on day 1 and included 3,000 cGy in 15 fractions. Surgery took place on day 55, and one more cycle of chemotherapy and an additional 3,000 cGy of RT began on day 85. RESULTS: Forty-one eligible patients (median follow-up, 53 months) were studied. N2 disease was present in 80%, whereas 20% had T3N0 or T3N1 lesions. Response to neoadjuvant chemotherapy and RT included no complete responses (CR), 21 (51%) partial responses (PR) or regressions, 19 (46%) stable disease (SD), and one (2%) progressive disease (PD). Thirty-one patients underwent surgery, and 25 were resected. In four of the 25 resection specimens, no viable tumor was present, whereas in three of the six unresectable patients, extensive biopsy results demonstrated only necrotic tumor. The maximum response achieved using all protocol treatment was 27 (66%) CRs, seven (17%) PRs or regression, six (15%) SDs, and one (2%) PD. Toxicity was substantial and primarily hematologic. There were six (15%) treatment-related deaths, which included three perioperative deaths and three chemotherapy-related toxicity deaths. The Kaplan-Meier curve indicated a 1-year survival of 58% and a median survival of 15.5 months. Nine patients (22%) remain disease-free. CONCLUSIONS: There was a reasonably high rate of PR associated with concurrent neoadjuvant chemotherapy and RT, and a high percentage of patients who ultimately were rendered completely disease-free. However, treatment-related morbidity and mortality was common. Median survival seemed to be only modestly improved beyond that achieved with less intensive means of treatment. However, a group has emerged of patients who enjoy prolonged disease-free survival and possible cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J. L., Li, S., Roig, J., Olazabal, A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401203300301 · Cited by 1,261
Dillman, R. O., Herndon, J., Seagren, S. L., Eaton, W. L., & Green, M. R. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.17.1210 · Cited by 923
Self-citationHellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Roth, J. A., Atkinson, E. N., Fossella, F., Komaki, R., Ryan, M. B., Putnam, J. B., Lee, J. S., Dhingra, H., De Caro, L., Chasen, M., et al. (1998) · Lung Cancer · doi:10.1016/s0169-5002(98)00046-4 · Cited by 447
ROSELL, R., GOMEZCODINA, J., CAMPS, C., JAVIERSANCHEZ, J., MAESTRE, J., PADILLA, J., CANTO, A., ABAD, A., & ROIG, J. (1999) · Lung Cancer · doi:10.1016/s0169-5002(99)00045-8 · Cited by 393
Martini, N., Kris, M. G., Flehinger, B. J., Gralla, R. J., Bains, M. S., Burt, M. E., Heelan, R., McCormack, P. M., Pisters, K. M. W., Rigas, J. R., et al. (1993) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(93)91072-u · Cited by 373
Sun, A., Bae, K., Gore, E. M., Movsas, B., Wong, S. J., Meyers, C. A., Bonner, J. A., Schild, S. E., Gaspar, L. E., Bogart, J. A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6053 · Cited by 369
Eberhardt, W., Wilke, H., Stamatis, G., Stuschke, M., Harstrick, A., Menker, H., Krause, B., Müeller, M. R., Stahl, M., Flasshove, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.622 · Cited by 328
Gore, E. M., Bae, K., Wong, S. J., Sun, A., Bonner, J. A., Schild, S. E., Gaspar, L. E., Bogart, J. A., Werner-Wasik, M., & Choy, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.1609 · Cited by 308
Evaluation of lymph nodes with RECIST 1.1
Schwartz, L. H., Bogaerts, J., Ford, R., Shankar, L., Therasse, P., Gwyther, S., & Eisenhauer, E. A. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.028 · Cited by 298
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.
Martin, J., Ginsberg, R. J., Venkatraman, E. S., Bains, M. S., Downey, R. J., Korst, R. J., Kris, M. G., & Rusch, V. W. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.092 · Cited by 195
Metadata
- Authors
- Strauss, G. M., Herndon, J. E., Sherman, D. D., Mathisen, D. J., Carey, R. W., Choi, N. C., Rege, V. B., Modeas, C., & Green, M. R.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-08
- Volume
- 10
- Issue
- 8
- Pages
- 1237-1244
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2155709777
- Cited by
- 211
- References
- 0
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.